FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2641-2643 June 21, 2007 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by McMahon, M. A. PubMed Citation

The truly remarkable advances in the treatment of human immunodeficiency virus type 1 (HIV-1) infection have turned a once nearly uniform death sentence into a treatable condition. The survival benefits resulting from the use of antiretroviral drugs are estimated to have saved 3 million years of life; these benefits compare favorably with those of many other interventions for chronic diseases.¹ In the 20 years since zidovudine was first approved, more than 20 other antiretroviral drugs have emerged, including inhibitors of HIV-1 reverse transcriptase, protease, and attachment and entry. Several other experimental agents now in expanded-access programs may be approved in . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Massachusetts General Hospital, Boston, and the Partners AIDS Research Center, Cambridge, MA.

This article has been cited by other articles:

• Tchesnokov, E. P., Obikhod, A., Schinazi, R. F., Gotte, M. (2008). Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse Transcriptase. J. Biol. Chem. 283: 34218-34228 [Abstract] [Full Text]  
• Dienstag, J. L. (2008). Hepatitis B Virus Infection. NEJM 359: 1486-1500 [Full Text]  
• (2007). Caution Regarding Use of Entecavir in HIV/HBV Coinfected Patients. JWatch Infect. Diseases 2007: 1-1 [Full Text]